Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

346.46USD
3:33pm BST
Change (% chg)

$-0.56 (-0.16%)
Prev Close
$347.02
Open
$347.04
Day's High
$347.04
Day's Low
$345.52
Volume
48,479
Avg. Vol
620,108
52-wk High
$388.67
52-wk Low
$249.24

Latest Key Developments (Source: Significant Developments)

Biogen Inc To Repurchase Up To $3.5 Bln Of Company's Common Stock
Friday, 3 Aug 2018 

Aug 3 (Reuters) - Biogen Inc ::BIOGEN INC - DIRECTORS AUTHORIZED A PROGRAM TO REPURCHASE UP TO $3.5 BILLION OF THE COMPANY’S COMMON STOCK.BIOGEN INC SAYS 2018 SHARE REPURCHASE PROGRAM DOES NOT HAVE AN EXPIRATION DATE - SEC FILING.BIOGEN INC - ALL SHARE REPURCHASES UNDER 2018 SHARE REPURCHASE PROGRAM WILL BE RETIRED.  Full Article

Biogen Reports Qtrly Non-GAAP Earnings Per Share Of $5.80
Tuesday, 24 Jul 2018 

July 24 (Reuters) - Biogen Inc ::BIOGEN Q2 2018 REVENUES INCREASE 9% TO $3.4 BILLION.QTRLY EARNINGS PER SHARE (EPS) ATTRIBUTABLE TO BIOGEN INC. $4.18.QTRLY NON-GAAP EARNINGS PER SHARE $5.80.Q2 EARNINGS PER SHARE VIEW $5.21, REVENUE VIEW $3.25 BILLION -- THOMSON REUTERS I/B/E/S.IN Q2 GAAP DILUTED EPS IMPACTED BY $2.84 RELATED TO COLLABORATION AGREEMENT WITH IONIS PHARMACEUTICALS, AMONG OTHERS.QTRLY TECFIDERA REVENUE $1,087 MILLION VERSUS $1,111 MILLION.ACQUIRES MUSCLE ENHANCEMENT PROGRAM FROM ALIVEGEN.QTRLY SPINRAZA REVENUE $423 MILLION VERSUS $203 MILLION.ACQUISITION FROM ALIVEGEN INCLUDES AN UPFRONT PAYMENT OF $27.5 MILLION.UPDATING ITS FULL YEAR 2018 FINANCIAL GUIDANCE.2018 REVENUE EXPECTED TO BE ABOUT $13.0 BILLION TO $13.2 BILLION.BIOGEN - AS PER DEAL, MAY PAY ALIVEGEN UP TO $535 MILLION IN ADDITIONAL POTENTIAL DEVELOPMENT, COMMERCIALIZATION MILESTONES ACROSS BOTH ASSETS & MULTIPLE INDICATIONS.2018 GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $21.80 AND $22.40.2018 NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $24.90 AND $25.50.FY2018 EARNINGS PER SHARE VIEW $23.97, REVENUE VIEW $12.97 BILLION -- THOMSON REUTERS I/B/E/S.HAS ACQUIRED ALG-801 (PHASE 1A) AND ALG-802 (PRECLINICAL) FROM ALIVEGEN INC.  Full Article

Biogen Exercises Option To Increase Ownership In Samsung Bioepis
Thursday, 28 Jun 2018 

June 28 (Reuters) - Biogen Inc ::BIOGEN EXERCISES OPTION TO INCREASE OWNERSHIP IN SAMSUNG BIOEPIS.BIOGEN INC - WILL PAY SAMSUNG BIOLOGICS APPROXIMATELY $700 MILLION TO INCREASE ITS OWNERSHIP IN SAMSUNG BIOEPIS TO APPROXIMATELY 49.9%.BIOGEN INC - DEAL INCREASING BIOGEN'S OWNERSHIP IN SAMSUNG BIOEPIS FROM APPROXIMATELY 5.4% TO APPROXIMATELY 49.9%.  Full Article

Alkermes Says Receives $50 Million Payment From Biogen
Wednesday, 6 Jun 2018 

June 6 (Reuters) - Alkermes Plc ::ALKERMES RECEIVES $50 MILLION PAYMENT FROM BIOGEN FOLLOWING REVIEW OF PRELIMINARY GASTROINTESTINAL TOLERABILITY DATA FROM THE ONGOING BIIB098 CLINICAL DEVELOPMENT PROGRAM.ALKERMES PLC - ALKERMES EXPECTS TO SUBMIT A NEW DRUG APPLICATION (NDA) FOR BIIB098 TO U.S. FOOD AND DRUG ADMINISTRATION (FDA) IN Q4 OF 2018.ALKERMES PLC - ALL OF PAYMENT WILL BE RECORDED AS LICENSE REVENUE IN ALKERMES' FINANCIAL RESULTS FOR QUARTER ENDING JUNE 30, 2018.ALKERMES - MAY ALSO RECEIVE $150 MILLION MILESTONE PAYMENT FROM BIOGEN UPON FDA APPROVAL, ON OR BEFORE DEC. 31, 2021, OF NDA FOR BIIB098.  Full Article

Biogen Reports Quarterly Revenues Of $3.1 Billion
Tuesday, 24 Apr 2018 

April 24 (Reuters) - Biogen Inc ::BIOGEN REPORTS QUARTERLY REVENUES OF $3.1 BILLION.Q1 REVENUE $3.1 BILLION VERSUS I/B/E/S VIEW $3.16 BILLION.QTRLY NON-GAAP DILUTED EPS $6.05.QTRLY EARNINGS PER SHARE $5.54.QTRLY SPINRAZA REVENUE OF $364 MILLION VERSUS $47 MILLION REPORTED LAST YEAR.QTRLY PLEGRIDY REVENUE OF $100 MILLION VERSUS. $112 MILLION REPORTED LAST YEAR.QTRLY TYSABRI REVENUE OF $$462 MILLION VERSUS. $545 MILLION REPORTED LAST YEAR.QTRLY TECFIDERA REVENUE OF $987 MILLION VERSUS $958 MILLION REPORTED LAST YEAR.QTRLY AVONEX REVENUE OF $451 MILLION VERSUS $537 MILLION REPORTED LAST YEAR.Q1 EARNINGS PER SHARE VIEW $5.94 -- THOMSON REUTERS I/B/E/S.  Full Article

Biogen, Samsung Bioepis To Settle With AbbVie Over Humira Biosimilar
Thursday, 5 Apr 2018 

April 5 (Reuters) - Biogen Inc ::BIOGEN AND SAMSUNG BIOEPIS AGREE TO SETTLEMENT WITH ABBVIE ALLOWING COMMERCIALIZATION OF IMRALDI™ (ADALIMUMAB BIOSIMILAR) IN EUROPE.BIOGEN EXPECTS TO LAUNCH IMRALDI IN EUROPE ON OCTOBER 16, 2018.PRECISE TERMS OF AGREEMENT WITH ABBVIE ARE CONFIDENTIAL.UNDER TERMS OF AGREEMENT, ABBVIE WILL GRANT PATENT LICENSES FOR USE AND SALE OF IMRALDI IN EUROPE.COUNTRY BASIS.UNDER TERMS OF AGREEMENT, BIOGEN AND SAMSUNG BIOEPIS WILL MAKE ROYALTY PAYMENTS TO ABBVIE.COMPANIES HAVE AGREED TO DISMISS ALL PENDING PATENT LITIGATION.  Full Article

Biogen Inc Reports Qtrly Loss Per Share Of $1.40
Thursday, 25 Jan 2018 

Jan 25 (Reuters) - Biogen Inc ::BIOGEN REPORTS RECORD REVENUES FOR BOTH THE FULL YEAR AND FOURTH QUARTER OF 2017, $12.3 BILLION AND $3.3 BILLION, RESPECTIVELY.2018 FULL YEAR REVENUE GUIDANCE OF $12.7 TO $13.0 BILLION.2017 GAAP EPS DECREASED 30%, INCLUDING A $1.2 BILLION CHARGE DUE TO U.S. TAX REFORM.QTRLY ‍NON-GAAP DILUTED EPS $5.26​.QTRLY LOSS PER SHARE $1.40.QTRLY PLEGRIDY REVENUE OF $125​ MILLION VERSUS. $125 MILLION.QTRLY TYSABRI REVENUE OF $463​ MILLION VERSUS. $474 MILLION.GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $22.20 AND $23.20 FOR 2018.QTRLY TECFIDERA REVENUE OF $1,076 MILLION VERSUS. $1,002 MILLION.NON-GAAP DILUTED EPS IS EXPECTED TO BE BETWEEN $24.20 AND $25.20 FOR 2018.QTRLY AVONEX REVENUE OF $520 MILLION VERSUS. $564 MILLION.FY2018 EARNINGS PER SHARE VIEW $24.16, REVENUE VIEW $12.68 BILLION -- THOMSON REUTERS I/B/E/S.Q4 EARNINGS PER SHARE VIEW $5.45, REVENUE VIEW $3.08 BILLION -- THOMSON REUTERS I/B/E/S.QTRLY TOTAL REVENUES $3,307 MILLION VERSUS $2,872 MILLION LAST YEAR.‍IN Q4 CO BOOKED A GAAP & NON-GAAP TAX CHARGE OF $42 MILLION & $50 MILLION, RESPECTIVELY, RELATED TO IMPAIRMENT OF ZINBRYTA RELATED TAX ASSETS​.  Full Article

Biogen Responds To Coverage Recommendation By The Canadian Drug Expert Committee (Cdec) For Spinraza
Friday, 22 Dec 2017 

Dec 22 (Reuters) - Biogen Inc ::BIOGEN RESPONDS TO COVERAGE RECOMMENDATION BY THE CANADIAN DRUG EXPERT COMMITTEE (CDEC) FOR SPINRAZA, THE ONLY TREATMENT APPROVED FOR TREATMENT OF 5Q SPINAL MUSCULAR ATROPHY (SMA).BIOGEN - CDEC'S RECOMMENDATION DISAPPOINTS AS CLINICAL CRITERIA, CONDITIONS LIMIT PATIENTS WITH SMA THAT COULD POTENTIALLY BENEFIT FROM SPINRAZA.  Full Article

Biogen, Ionis Collaborate To Identify Novel Therapies To Treat Spinal Muscular Atrophy
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Biogen Inc ::BIOGEN AND IONIS ENTER INTO NEW COLLABORATION TO IDENTIFY NOVEL THERAPIES FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY.BIOGEN WILL HAVE OPTION TO LICENSE THERAPIES ARISING OUT OF THE COLLABORATION.‍IONIS WILL RECEIVE A $25 MILLION UPFRONT PAYMENT AND WILL EARN DEVELOPMENT AND REGULATORY MILESTONE PAYMENTS FROM BIOGEN.BIOGEN WILL BE RESPONSIBLE FOR THE DEVELOPMENT AND COMMERCIALIZATION.ON COMMERCIALIZATION OF NOVEL THERAPIES TO TREAT SPINAL MUSCULAR ATROPHY​, BIOGEN TO PAY IONIS PERFORMANCE MILESTONES, ROYALTIES ON NET SALES.  Full Article

Sarissa Capital Management's Alexander​ ‍Denner Buys 30,000 Shares Of Biogen's Common Stock
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Biogen Inc ::SARISSA CAPITAL MANAGEMENT'S ALEXANDER​ ‍DENNER REPORTS PURCHASE OF 30,000 SHARES OF BIOGEN INC'S COMMON STOCK BETWEEN NOV 28-29 - SEC FILING.  Full Article

EU mergers and takeovers (Sept 11)

BRUSSELS, Sept 11 The following are mergers under review by the European Commission and a brief guide to the EU merger process: